Figure 2.
Figure 2. Delayed clot retraction in CD151-deficient platelets in the presence of normal integrin αIIbβ3 expression. (A) Photographs showing the kinetics of in vitro clot retraction using platelet-rich plasma (PRP) (normalized platelet counts) from wild-type and CD151–/– mice. Samples were treated with 10 nM thrombin. Red blood cells (5 μL) were added to enhance color contrast for photography. Each photograph is representative of 3 independent experiments. (B) Surface expression of integrin β3 on platelets was determined by staining with a buffer control, isotype control FITC-CD3 mAb, positive control FITC-CD44 mAb, FITC-CD9, and FITC-integrin β3 mAb for both wild-type and CD151–/– platelets. FITC-labeled samples were analyzed on a FACS Calibur analyzer. Results are representative of 3 independent experiments. The data represent the mean fluorescence intensity (MFI) ± SEM.

Delayed clot retraction in CD151-deficient platelets in the presence of normal integrin αIIbβ3 expression. (A) Photographs showing the kinetics of in vitro clot retraction using platelet-rich plasma (PRP) (normalized platelet counts) from wild-type and CD151–/– mice. Samples were treated with 10 nM thrombin. Red blood cells (5 μL) were added to enhance color contrast for photography. Each photograph is representative of 3 independent experiments. (B) Surface expression of integrin β3 on platelets was determined by staining with a buffer control, isotype control FITC-CD3 mAb, positive control FITC-CD44 mAb, FITC-CD9, and FITC-integrin β3 mAb for both wild-type and CD151–/– platelets. FITC-labeled samples were analyzed on a FACS Calibur analyzer. Results are representative of 3 independent experiments. The data represent the mean fluorescence intensity (MFI) ± SEM.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal